Download PDF
Thromb Haemost 2004; 92(01): 208-210
DOI: 10.1055/s-0037-1613642
Case Report
Schattauer GmbH

Intraoperative management of a congenital antithrombin deficient patient on chronic hemodialysis

Tomohiko Hara
1   Department of Urology, Kokura Memorial Hospital, Kokurakita-ku, Kitakyushu, Fukuoka, Japan
,
Kazutaka Jojima
1   Department of Urology, Kokura Memorial Hospital, Kokurakita-ku, Kitakyushu, Fukuoka, Japan
,
Keiji Takeuchi
1   Department of Urology, Kokura Memorial Hospital, Kokurakita-ku, Kitakyushu, Fukuoka, Japan
,
Kimio Takai
2   Department of Urology, Yamaguchi University School of Medicine, Yamaguchi, Japan
,
Katsusuke Naito
2   Department of Urology, Yamaguchi University School of Medicine, Yamaguchi, Japan
› Author Affiliations
Further Information

Publication History

Received 29 November 2003

Accepted after revision 02 April 2004

Publication Date:
15 December 2017 (online)

    Permissions and Reprints

 

 

  • References

  • 1 Matsuo T, Yamada T, Yamanashi T. et al. Choice of anticoagulant in a congenital antithrombin III (AT III) deficient patient with chronic renal failure undergoing regular haemodialysis. Clin Lab Haematol 1989; 11 (03) 213-9.
    CrossrefPubMedGoogle Scholar
  • 2 Ota K, Akizawa T, Hirasawa Y. et al. Effect of argatroban as an anticoagulant for haemodialysis in patients in patients with antithrombin III deficiency. Nephrol Dial Transplant 2003; 18: 1623-30.
    CrossrefPubMedGoogle Scholar
  • 3 Beresford CH. Antithrombin III deficiency. Blood Rev 1988; 02 (04) 239-50.
    CrossrefPubMedGoogle Scholar
  • 4 O’Shea SI, Ortel TL, Kovalik EC. Alternative Methods of Anticoagulation for Dialysis-dependent Patients with Heparin-induced Thrombocytopenia. Semin Dial 2003; 16 (01) 61-7.
    CrossrefPubMedGoogle Scholar
  • 5 Swan SK, St Peter JV, Lambrecht LJ. et al. Comparison of anticoagulant effects and safety of argatroban and heparin in healthy subjects. Pharmacotherapy 2000; 20 (07) 756-70.
    CrossrefPubMedGoogle Scholar
  • 6 Tengborn L, Bergqvist D. Surgery in patients with congenital antithrombin III deficiency. Acta Chir Scand 1988; 154 (03) 179-83.
    PubMedGoogle Scholar
  • 7 Lewis BE, Wallis DE, Berkowitz SD. et al. argatroban anticoagulant therapy in patients with heparin-induced thrombocytopenia. Circulation 2001; 103 (14) 1838-43.
    CrossrefPubMedGoogle Scholar
  • 8 Kathiresan S, Shiomura J, Jang IK. Argatroban. J Thromb Thrombolysis 2002; 13 (01) 41-7.
    CrossrefPubMedGoogle Scholar
  • 9 Swan SK, Hursting MJ. The pharmacokinetics and pharmacodynamics of argatroban: effects of age, gender, and hepatic or renal dysfunction. Pharmacotherapy 2000; 20 (03) 318-29.
    CrossrefPubMedGoogle Scholar
  • 10 Sundaram S, Gikakis N, Hack CE. et al. Nafamostat mesilate, a broad spectrum protease inhibitor, modulates platelet, neutrophil and contact activation in simulated extracorporeal circulation. Thromb Haemost 1996; 75 (01) 76-82.
    Article in Thieme ConnectPubMedGoogle Scholar